New Active Agents for Therapy, Diagnostics and Prophylaxis of Alzheimer and TSE-related Diseases
The invention relates to a new chemical class of compounds, which modulate the aggregation of amyloidogenetic proteins or peptides. The heterocylic or aromatic active compounds, with the general structure as shown in the figure above, are able to form a complex with amyloidogenetic proteins or peptides according to the donor-acceptor-donor pattern, leading to inhibition of the amyloid aggregation.
Next to the compounds and the use of the compounds, the invention also covers a proprietary method for the synthesis of the compounds.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
You are What You Eat—Stanford Study Links Fiber to Anti-Cancer Gene Modulation
The Fiber Gap: A Growing Concern in American Diets Fiber is well known to be an important part of a healthy diet, yet less than 10% of Americans eat the minimum recommended…
Trust Your Gut—RNA-Protein Discovery for Better Immunity
HIRI researchers uncover control mechanisms of polysaccharide utilization in Bacteroides thetaiotaomicron. Researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius-Maximilians-Universität (JMU) in Würzburg have identified a…
ASXL1 Mutation: The Hidden Trigger Behind Blood Cancers and Inflammation
Scientists show how a mutated gene harms red and white blood cells. LA JOLLA, CA—Scientists at La Jolla Institute for Immunology (LJI) have discovered how a mutated gene kicks off…